논문 상세보기

2’-Fucosyllactose가 마우스 배변 및 장내 미생물에 미치는 영향 KCI 등재

Effects of 2’-Fucosyllactyose on Defecation and Intestinal Microbiota in Mice

  • 언어KOR
  • URLhttps://db.koreascholar.com/Article/Detail/423365
구독 기관 인증 시 무료 이용이 가능합니다. 4,000원
한국식품영양학회지 (The Korean Journal of Food And Nutrition)
한국식품영양학회 (The Korean Society of Food and Nutrition)
초록

Prebiotics are known as components of intestinal microbiota that can improve and maintain human health status by stimulating the growth and activity of the intestinal tract as a method of controlling the intestinal environment. In this study, we examined whether 2’-fucosyllactose (FL) could affect intestinal microbial population and bowel activity. Water content and frequency of mouse feces were increased in the 2’-FL treated group at a high concentration (1,000 mg/kg), with brightness of the color enhanced and physical properties diluted. In addition, intestinal microbial analysis showed that harmful bacteria Clostridium and Staphylococcus strains were decreased and beneficial bacteria such as Lactobacillus strains were markedly increased in the group treated with a high concentration of 2’-FL compared to those in the control group. These findings suggest that administration of 2’-FL can maintain healthy bowel activity by reducing harmful bacteria population and improving diluted physical properties.

목차
Abstract
서 론
재료 및 방법
    1. 실험재료 및 시험물질 조제
    2. 실험동물의 사육
    3. 분변 시료 수집 및 분변 빈도 평가
    4. 분변 수분함량 평가
    5. 장내 미생물 평가
    6. 통계분석
결과 및 고찰
    1. 모유올리고당 2’-FL 투여에 따른 마우스 체중 변화 및분변 빈도 평가
    2. 모유올리고당 2’-FL 투여에 의한 분변 수분함량 평가
    3. 모유올리고당 2’-FL 투여에 따른 분변의 물리적 특성평가
    4. 모유올리고당2’-F의투여에따른장내미생물변화분석
요약 및 결론
감사의 글
References
저자
  • 김한해(한국한의학연구원 UST 학생연구원) | Han Hae Kim (Graduate School Student, Korean Medicine Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Korea)
  • 김연지(한국한의학연구원 연구원) | Yeon Ji Kim (Researcher, Korean Medicine Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Korea)
  • 김광연(한국한의학연구원 연구원) | Kwang-Youn Kim (Researcher, Korean Medicine Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Korea)
  • 신철수(㈜에이피테크놀로지 대표이사) | Chul Soo Shin (CEO, Advanced Protein Technologies Corp., Suwon 16229, Korea)
  • 윤종원(㈜에이피테크놀로지 연구소장) | Jong-Won Yoon (Center Director, Advanced Protein Technologies Corp., Suwon 16229, Korea)
  • 전선민(㈜에이피테크놀로지 연구위원) | Seon-min Jeon (Researcher, Advanced Protein Technologies Corp., Suwon 16229, Korea)
  • 김보미(㈜에이피테크놀로지 연구위원) | Bo-Mee Kim (Researcher, Advanced Protein Technologies Corp., Suwon 16229, Korea)
  • 방정수(㈜에이피테크놀로지 연구위원) | Jeongsu Bang (Researcher, Advanced Protein Technologies Corp., Suwon 16229, Korea)
  • 김경호(한국한의학연구원 책임연구원) | Kyungho Kim (Principal Researcher, Korean Medicine Application Center, Korea Institute of Oriental Medicine, Daegu 41062, Korea) Corresponding author